Summary Serum CA 125, quantified by an immunoradiometric assay employing the monoclonal antibody OC125 was found to be elevated in 48/58 (83%) of patients with established ovarian cancer. All histological types of carcinoma were antigen positive and there was a positive correlation between the frequency and level of serum CA125 and body burden of tumour. Twenty patients undergoing chemotherapy had serial CA125 estimations following a prospective protocol. Variation in CA125 level reflected disease progression or regression in 21/23 instances. Three of 9 patients tested showed an acute elevation of CA125 in the first week following chemotherapy and this effect predicted a good response to treatment. The natural half-life of CA125 in serum was estimated at -4.8 days, sufficiently short to allow changes in tumour volume to be rapidly reflected by a change in circulating antigen level. Although none of 15 patients with non-Hodgkin lymphoma demonstrated antigen levels outside the normal range, 11/27 patients with non-ovarian adenocarcinoma showed elevated CA125 levels, a specificity of 58% for this latter group. The value of CA125 in the management of ovarian malignancy is discussed.
The natural history of malignant ovarian tumours, which includes local invasion of tissues deep within the pelvis and the frequent presence of peritoneal seedling metastases prevents early diagnosis of the disease and once the diagnosis has been made, hinders accurate monitoring of disease status. Of currently available methods, CAT scanning increases the information available, even after recent laparotomy (Johnson et al., 1983) and despite limitations in detecting peritoneal seedlings and the logistical difficulties of repetition at monthly intervals, it remains the most useful noninvasive technique in common use. Second-look laparotomy which can accurately detect residual or recurrent disease, has been advocated to determine an end point for chemotherapy (Smith et al., 1976; Cohen et al., 1983) . However this has not resulted in improved survival (Cohen et al., 1983) and its place in overall management remains unclear. The introduction of intensive combination chemotherapy has improved response rates and median survival and has emphasised the need for an effective marker in this disease.
Several antigens have been detected in association with ovarian carcinomas (Donaldson et al., 1980; Bast et al., 1981; Bhattacharya et al., 1982) and of these CA125 has shown the most clinical promise to date Canney et al., 1984) . CA 125, a high molecular weight glycoprotein expressed in coelomic epithelium during embryonic development, is defined by a murine monoclonal antibody raised against a serous ovarian carcinoma cell line, OVCA 433. A radioimmunoassay to detect CA 125 in serum has been developed by Bast et al. (1983) and the object of this study was to assess its potential as a marker for established ovarian cancer.
Patients and methods
The sera of 58 patients with histologically proven ovarian carcinomas, of all histological types, were examined for CA125 levels. All Serum samples were separated within 4 h of collection and stored at -20°C until required. Half-lives have been calculated to the point where the antigen level entered the normal range. The upper limit of normal was taken as 35Uml-1, a level exceeded by 1% of 888 blood donors, .
Results

Sensitivity
The proportion of patients with ovarian carcinomas having elevated CA125 levels is shown in Table I , the overall sensitivity being 83%. The antigen was detectable irrespective of histological type, but whether the frequency of detection in mucinous, endometroid and clear cell carcinoma was similar . The plateau level of 11.3 Uml-1, which corresponds closely to the levels seen following complete resection of early stage tumours, is likely to be a more realistic goal, but, by analogy with testicular tumour markers, the end-point for therapy is likely to be a number of courses beyond such marker remission (Newlands et al., 1980) , which number has yet to be determined. Extended follow-up should establish this.
In conclusion, the potential benefits of a tumour marker in monitoring therapy may be defined as a reduction of toxicity by avoidance of ineffective or excessive treatment and improvement in overall survival by allowing effective treatment to be adjusted to the needs of the individual. Furthermore the potential for rapid assessment of chemotherapeutic regimens using a marker allows improvements to occur at an accelerated rate to the benefit of all, even marker negative patients. The sensitivity of CA125 for established ovarian carcinoma and the close relationship to clinical and radiological changes in response to treatment are likely to have a profound effect upon management of this disease.
The poor specificity limits the diagnostic utility in patients with proven adenocarcinoma and precludes CA125 estimation being used as a screening method for asymptomatic patients. However, the diagnostic and prognostic significance of elevated CA 125 levels pre-operatively have yet to be determined. Further investigation is needed in the above areas as well as to evaluate its potential use in the management of other non-ovarian adenocarcinomas.
